USING A SABA INHALER 3 OR MORE TIMES A WEEK IS AN INDICATOR OF INCREASED RISK OF ASTHMA ATTACKS1

Experts have co-developed a 5-item questionnaire to assess reliance. Click below to view the Blue Reliever Reliance test.

are your asthma patients over-reliant on their saba inhaler?

*SABA = Short-Acting Beta Agonist
'SABA Inhaler' is also the 'Blue Inhaler'

Asthma is due to chronic airway inflammation4. Although SABA also commonly known as the "Blue Reliever Inhaler" provides quick relief of symptoms which last for 3-6 hours5. over-reliance (e.g. patients use SABA three or more times a week) is associated with increased risk of exacerbations.1

Meanwhile, using three or more canisters per year is associated with two times likelihood of hospitalisation.2

Some patients see their blue reliever inhaler as the most important part of their asthma treatment without recognizing that SABA monotherapy will worsen asthma inflammation6.

This short test is designed to assess what your patients think of their SABA inhaler and if they may be relying on it too much

YOUR PATIENT’S VIEWS ABOUT THEIR BLUE RELIEVER INHALER

Take the short test now to get first-hand experience of the feedback patients will receive based on their responses

 

 

 

Loading......

This is not medical advice for patients to stop taking their medicine. The programme is designed to support conversations between healthcare professionals and patients.

IPCRG VERSION 2.0.

This is not medical advice for patients to stop taking their medicine. The programme is designed to support conversations between healthcare professionals and patients.

REFERENCES

1. NPJ Prim Care Respir Med. 2014;24:14009.
2. Global Initiative for Asthma (GINA). Available at: https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf (last accessed December 2019).
3. Psychology & Health. 1999;14(1):1–24.
4. Asthma: Definition. Chronic Respiratory Diseases. World Health Organization. Available at: "https://www.who.int/respiratory/asthma/definition/en/.
5. Billington CK, Penn RB and Hall IP. Handb Exp Pharmacol. 2017 ; 237: 23–40. doi:10.1007/164_2016_64.
6. Edwards MR, et al. J Biol Chem. 2007;282:15366-15375;

This site is intended for healthcare professionals